CHEK2 I157T

CI-VAR-00001979Explore in graph →NP_009125.1:p.Ile157ThrNM_007194.3:c.470T>CClinVar 5591 CIViC 787 rs17879961

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Prostate Neoplasm1
CHEK2 I157T	(predisposing)	Predisposing	B	Supports Predisposition	3	accepted	EID1852 Meta-analysis of 4 retrospective studies linked CHEK2 I157T to a higher risk of prostate cancer (OR 1.80; 95% confidence interval: 1.51-2.14; P = 0.00). PMID 26629066 · Wang et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
5591	Conflicting classifications of pathogenicity; risk factor	criteria provided, conflicting classifications	1	CHEK2-related cancer predisposition; Hereditary cancer-predisposing syndrome; Familial cancer of breast; Breast and colorectal cancer, susceptibility to; Gastrointestinal carcinoma; Adrenal cortex carcinoma; Malignant tumor of breast; Breast and/or ovarian cancer; Predisposition to cancer; TUMOR PREDISPOSITION SYNDROME 4, BREAST/PROSTATE/COLORECTAL; Prostate cancer; CHEK2-related disorder; Familial prostate cancer; Bone osteosarcoma; Colorectal cancer; Cystic fibrosis